![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Catalent, a global leader in clinical supply services, announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.
Operating in partnership with the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both local customers, and global biotech and pharmaceutical companies. The facility will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.
The facility will offer extensive clinical supply services including access to Catalent’s FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.
ABOUT CATALENT CLINICAL SUPPLY SERVICES
Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
